At the press conference of the National Health Insurance Administration held today, Huang Xinyu, director of the Department of Pharmaceutical Management of the National Health Insurance Administration, said that since the establishment of the National Health Insurance Administration, under the premise of adhering to the basics, it has vigorously supported the development of innovative drugs by including innovative drugs in the medical insurance catalog in a timely manner and supporting the acceleration of clinical application. As of the end of October this year, the cumulative expenditure of negotiated drugs and medical insurance during the agreement period has reached 244.7 billion yuan, driving the sales of related drugs to 354 billion yuan. In terms of supporting innovation, the following measures have been taken:
First, a dynamic adjustment mechanism for the medical insurance catalogue adapted to the access of new drugs has been established, and a dynamic adjustment mechanism for the catalogue has been established once a year, shortening the adjustment cycle from the original maximum of 8 years to one year. The scope of the application mainly focuses on the newly listed drugs in the past five years, and the proportion of newly listed drugs in the catalog in the current year has increased from 32% in 2019 to 97 in 20236%。In 2023, 57 varieties will be approved and included in the catalogue in the same year, the time from approval to listing of new drugs to the catalogue will be shortened from more than 5 years to more than one year now, and 80% of new drugs can enter the medical insurance drug catalogue within two years after listing.
Second, a lot of policy preferences have been given to the inclusion of innovative drugs in the medical insurance catalog, and a support mechanism covering the whole process of application, review, calculation, and negotiation has been established. In 2023, 25 innovative drugs will participate in the negotiations, and 23 will be negotiated, with a success rate of 92%. The success rate is 74 percentage points, the average decline is 44 percentage points. Through negotiations, the best innovative drugs have become more reasonable, the affordability of patients has been greatly improved, and most of them have seen a sharp increase in sales and revenue.
Third, the rules for the negotiation and renewal of innovative drugs to support the development of innovative drugs have been improved, and the number and reduction of price reductions of drugs for renewal and new indications have been appropriately controlled, so as to give new drug companies a stable expectation. According to this year's adjusted renewal rules, among the 100 renewed drugs this year, 70% of the drugs were renewed at the original price, and 31 varieties needed to be reduced because their sales exceeded expectations, and the average reduction rate was only 67%。At the same time, 18 of the 100 renewed drugs have added new indications, and only one has triggered the price reduction mechanism, and the others have not triggered the price reduction mechanism, and the original price has increased the indication. Relevant data show that from 2015 to 2022, 80% of the top 20 drugs in the national clinical drug amount have changed, and the most advanced new drugs have replaced some of the original drugs with less accurate and higher efficacy, and the majority of insured people have used drugs with better effects, better quality and more suitable drugs.
**: CCTV news client